NHS Rolls Out Life-Extending Drug for Hundreds of Women with Ovarian Cancer
Reported byNHS England ↗·Sourced by Goodlede
NICE recommendation for mirvetuximab soravtansine (Elahere) approved for folate-receptor-alpha positive platinum-resistant ovarian cancer; clinical trial showed 3.9-month median survival extension and 1.6-month progression delay versus chemotherapy; ~270 patients eligible in year one.
Applies only to FRĪ±-positive tumors (~32% of ovarian cancers); drug has significant ocular toxicity (up to 12.3% of patients); previous NHS treatment option was early 2000s, not strictly 'over 20 years' for all patients.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at NHS England
Read original story ↗↻ Refreshed daily
More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede
Equality
Launch of Advancing Women's Rights and Gender Equality
Amman Center for Human Rights Studies · Verified
Animals
European Commission Adopts Roadmap to Phase Out Animal Testing for Chemical Safety
European Commission via Rise for Animals · Verified
Science & Health
AI-designed Universal Coronavirus Vaccine Passes First Human Trial
ScienceDaily · Verified